Synovial Sarcoma - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 125 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Synovial Sarcoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Synovial Sarcoma - Pipeline Review, H1 2016', provides an overview of the Synovial Sarcoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Synovial Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Synovial Sarcoma
- The report reviews pipeline therapeutics for Synovial Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Synovial Sarcoma therapeutics and enlists all their major and minor projects
- The report assesses Synovial Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Synovial Sarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Synovial Sarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Synovial Sarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Synovial Sarcoma Overview 7
Therapeutics Development 8
Pipeline Products for Synovial Sarcoma - Overview 8
Pipeline Products for Synovial Sarcoma - Comparative Analysis 9
Synovial Sarcoma - Therapeutics under Development by Companies 10
Synovial Sarcoma - Therapeutics under Investigation by Universities/Institutes 11
Synovial Sarcoma - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Synovial Sarcoma - Products under Development by Companies 14
Synovial Sarcoma - Products under Investigation by Universities/Institutes 15
Synovial Sarcoma - Companies Involved in Therapeutics Development 16
Adaptimmune Therapeutics Plc 16
Advenchen Laboratories, LLC 17
EpiZyme, Inc. 18
Immune Design Corp. 19
Karyopharm Therapeutics, Inc. 20
Merck & Co., Inc. 21
Novartis AG 22
OncoTherapy Science, Inc. 23
Takara Bio Inc. 24
Synovial Sarcoma - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
AL-3818 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CMB-305 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
everolimus - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GSK-3377794 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
OTSA-101 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
pembrolizumab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
selinexor - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SSTC-104 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
tazemetostat - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
TBI-1301 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Synovial Sarcoma - Recent Pipeline Updates 69
Synovial Sarcoma - Discontinued Products 112
Synovial Sarcoma - Product Development Milestones 113
Featured News & Press Releases 113
Feb 09, 2016: U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune's Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma 113
Feb 02, 2016: Adaptimmune and GSK expand Strategic Immunotherapy Collaboration 113
Dec 30, 2015: Epizyme Announces First Patient Dosed in Global Clinical Program Evaluating Tazemetostat in Genetically Defined Solid Tumors 114
Nov 05, 2015: Adaptimmune Announces Data From Clinical Study of NY-ESO Affinity Enhanced T-Cell Therapy in Synovial Sarcoma at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer 116
Oct 30, 2015: Adaptimmune To Present new data from NY-ESO at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer 118
Sep 01, 2015: Adaptimmune Expands Trial of T-cell Therapy for Synovial Sarcoma and Achieves Clinical Milestones 118
Aug 24, 2015: Epizyme Announces Acceptance of Investigational New Drug Application for Tazemetostat in Patients with INI1-Negative Tumors or Synovial Sarcoma 119
May 30, 2015: Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 Specific T-Cells in Multiple Cancers at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting 121
May 21, 2015: Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting 122
May 13, 2015: Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting 123
Appendix 124
Methodology 124
Coverage 124
Secondary Research 124
Primary Research 124
Expert Panel Validation 124
Contact Us 124
Disclaimer 125

List of Tables
Number of Products under Development for Synovial Sarcoma, H1 2016 8
Number of Products under Development for Synovial Sarcoma - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Synovial Sarcoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 16
Synovial Sarcoma - Pipeline by Advenchen Laboratories, LLC, H1 2016 17
Synovial Sarcoma - Pipeline by EpiZyme, Inc., H1 2016 18
Synovial Sarcoma - Pipeline by Immune Design Corp., H1 2016 19
Synovial Sarcoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 20
Synovial Sarcoma - Pipeline by Merck & Co., Inc., H1 2016 21
Synovial Sarcoma - Pipeline by Novartis AG, H1 2016 22
Synovial Sarcoma - Pipeline by OncoTherapy Science, Inc., H1 2016 23
Synovial Sarcoma - Pipeline by Takara Bio Inc., H1 2016 24
Assessment by Monotherapy Products, H1 2016 25
Number of Products by Stage and Target, H1 2016 27
Number of Products by Stage and Mechanism of Action, H1 2016 29
Number of Products by Stage and Route of Administration, H1 2016 31
Number of Products by Stage and Molecule Type, H1 2016 33
Synovial Sarcoma Therapeutics - Recent Pipeline Updates, H1 2016 69
Synovial Sarcoma - Discontinued Products, H1 2016 112